Skip to content
GenomarkerCONTROLLED EARLY ACCESS
Log in

Request access

Access is reviewed, not sold.

Genomarker is in controlled early access while the public corpus audit completes. We onboard a small number of research teams, platform partners, and diligence engagements — so every early analysis strengthens the assurance system.

  • Research teams get supported analyses with assurance, evidence packages, and replay.
  • Platforms and agent builders get the Assurance API — schema discovery through signed evidence.
  • Investors and BD teams get Diligence: independent review of computational claims.

REQUESTS REVIEWED WITHIN 5 BUSINESS DAYS
NO SELF-SERVE SIGNUP · NO CREDIT CARD

Tell us about your work

Everything here helps us route your request to the right surface — Runtime, Assurance API, or Diligence.

Research teamPlatform / agent builderDiligence / investorOther
Reviewed by a human. We reply either way.